503. Gains in Patient Activation Measure (PAM) Scores at 12 Months

Code quality with a special plan:

1. Document a Diagnosis and Plan as you normally would.
2. Tap Special Plans and select MIPS.
3. From Popular Plans, select MIPS Quality and tap Save.
4. Locate the MIPS Quality plan and tap Resume.
5. Tap the PAM tab.
6. Select the appropriate options from the Quality 503 drop-downs.
7. Tap Done.
8. Document the rest of the visit and Finalize.

Eyefinity products and documentation refer to the MIPS quality numbers. Other measure numbering systems are listed here for your reference.

Quality	503
NQF	—
CMS	—

• Registry
• AAO IRIS
• MVP

This topic describes how points are calculated for this measure. To learn more about scoring, go to Scoring.

Benchmarks are displayed here as both a chart and a table. The chart gives you a visual representation and helps you quickly compare benchmarks across different reporting methods. The table lists the specific benchmark criteria for each available reporting method.

 

Submission Method	3rd Decile	4th Decile	5th Decile	6th Decile	7th Decile	8th Decile	9th Decile	10th Decile
Registry*	—	—	—	—	—	—	—	—
AAO IRIS*	—	—	—	—	—	—	—	—
MVP*	—	—	—	—	—	—	—	—

* Benchmarking data for this submission method was unavailable at the time of publication.

Patients 14 and over on the date of the encounter and at least two encounters during the performance period:

Denominator Exclusions

Diagnosis of dementia:

OR diagnosis of Huntington's disease:

OR diagnosis of cognitive impairment or Alzheimer’s disease:

OR diagnosis of delirium:

OR psychoactive substance abuse:

Denominator Exceptions

Documentation of patient reasons for patients who were not seen for the second PAM survey (e.g., less than four months between baseline PAM assessment and follow-up:

Patients who did not have a baseline PAM score and/or a second scoe within 4 to 12 months of baseline PAM score

The baseline PAM score can be captured during the current performance period or the prior performance period, however, the follow-up PAM score should be captured during the current performance period for the purposes of this measure.

Performance Met

Patients who had a baseline PAM score and a second score within 4 to 12 months of baseline PAM score:

Performance Not Met

Patients who did not have a baseline PAM score and/or a second score within 4 to 12 months of baseline PAM score:

All eligible instances when M1345 is submitted for Performance Met (patient received clinical follow-up and PAM score assessed at 4 to 12 months) in the Numerator 1.

AND patients 14 and over on the date of the encounter and at least two encounters during the performance period:

Denominator Exclusions

Patients who died during the performance period:

OR Diagnosis of dementia:

OR diagnosis of Huntington's disease:

OR diagnosis of cognitive impairment or Alzheimer’s disease:

OR diagnosis of delirium:

OR psychoactive substance abuse:

Denominator Exceptions

Documentation of patient reasons for patients who were not seen for the second PAM survey (e.g., less than four months between baseline PAM assessment and follow-up:

Patients who did not have a baseline PAM score and/or a second score within 4 to 12 months of baseline PAM score

A passing score for eligible patients would be to show an average net 3-point PAM score increase in a 4 to 12 month period. An excellent score for eligible patients would be to show an average net 6-point PAM score increase in a 4- to 12-month period. However, a PAM score of passing or excellent meets performance for this measure. If there are multiple PAM scores available, the most recent PAM score should be used for the follow-up PAM score, while the baseline PAM score should be the earliest PAM score that falls within the 4 to 12 months prior to the date of the follow-up.

Performance Met

Patients who achieved a net increase in PAM score of at least 3 points in a 4 to 12 month period (passing):

Performance Not Met

Patients who did not have a net increase in PAM score of at least 3 points within a 4 to 12 month period:

All eligible instances when M1345 is submitted for Performance Met (patient received clinical follow-up and PAM score assessed at 4 to 12 months) in the Numerator 1.

AND patients 14 and over on the date of the encounter and at least two encounters during the performance period:

Denominator Exclusions

Patients who died during the performance period:

OR Diagnosis of dementia:

OR diagnosis of Huntington's disease:

OR diagnosis of cognitive impairment or Alzheimer’s disease:

OR diagnosis of delirium:

OR psychoactive substance abuse:

Denominator Exceptions

Documentation of patient reasons for patients who were not seen for the second PAM survey (e.g., less than four months between baseline PAM assessment and follow-up:

Patients who did not have a baseline PAM score and/or a second score within 4 to 12 months of baseline PAM score

A passing score for eligible patients would be to show an average net 3-point PAM score increase in a 4 to 12 month period. An excellent score for eligible patients would be to show an average net 6-point PAM score increase in a 4- to 12-month period. However, a PAM score of passing or excellent meets performance for this measure. If there are multiple PAM scores available, the most recent PAM score should be used for the follow-up PAM score, while the baseline PAM score should be the earliest PAM score that falls within the 4 to 12 months prior to the date of the follow-up.

Performance Met

Patients who achieved a net increase in PAM score of at least 6-points in a 4 to 12 month period (excellent):

Performance Not Met

Patients who did not have a net increase in PAM score of at least 6 points within a 4 to 12 month period: